Current Members

PPTA members produce approximately 80% of the plasma protein therapies used in the United States today and more than 60% worldwide.

Global Members

Bio Products Laboratory
Biotest
CSL Behring
Grifols
Kedrion SpA
Takeda

European Members

Bio Products Laboratory
Biotest AG
CSL Behring GmbH
Grifols International SA
Kedrion SpA
Takeda

North America Members

ADMA Biologics, Inc.
Bio Products Laboratory
CSL Behring
Emergent BioSolutions
Grifols
Kedrion SpA
Takeda

Source Members

Access Plasma LLC
B Positive Plasma LLC
BioLife Plasma Services LP/(Takeda)
Biomat USA LLC
Biotest AG
Biotest Pharmaceuticals
Blood and Plasma Research Inc.
BPL Plasma Inc.
Canadian Plasma Resources
CSL Plasma
Europlasma GmbH
Hemarus LLC
Immunotek Bio Centers LLC
KEDPlasma LLC
Kedrion SpA
Octapharma Plasma
PlasmaVita
Prometic Plasma Resources
Scantibodies Biologics
Southern Blood Services
UNICAplasma s.r.o

Associate Members

Abbott Laboratories Diagnostic Division
ABO Pharmaceuticals
AOSS Medical Supply
Blood Centers of America (BCA)
Evolve Biologics Inc.
Fresenius Kabi
Haemonetics Corporation
Hemasource
Kamada Ltd.
Lychem International Ltd.
Marketing Research Bureau Inc.
National Genetics Institute
North Lane
Paysign, Inc.
PreviPharma Consulting GmbH
QualTex Laboratories
Roche Diagnostics
Secure Transfusion Services
Vizient Inc.

Membership

PPTA News

Study Shows Immunoglobulin Therapy is “Critical and Cost-Effective” in Treating CVID +

The journal publication, “Immunoglobulin Replacement Therapy is critical and cost-effective in increasing life expectancy and quality of life in patients suffering from Common Variable Immunodeficiency Disorders (CVID): A health-economic assessment,” is authored by Professor Philippe van Wilder with the Université libre de Bruxelles and Professor Esther de Vries of Tilburg University and offers a health economic model to estimate the value of treatment with IG therapy for CVID patients.
Read More
New position statement by CHMP regarding donor deferral criteria for sexual behaviour helps assessment of PMFs +

The International Plasma and Fractionation Association and the Plasma Protein Therapeutics Association are pleased with the recent publication by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) "CHMP Position statement on quality and safety assessment for the Plasma Master File (PMF) certification with regard to donor deferral criteria for sexual risk behaviour," as such a position was highly needed, especially regarding men-having-sex-with-men (MSM). It clarifies that the application of these nationally defined deferral periods will from now on also be considered when assessing appropriateness of locally collected plasma to be included in a PMF.
Read More
Lifting of long-time ban on use of UK plasma for manufacturing of immunoglobulins will help patients +

February 25, 2021 (Annapolis, MD) - The Plasma Protein Therapeutics Association (PPTA) welcomes the decision of the UK government to lift a two decades old ban on the use of UK-donated plasma for the manufacture of immunoglobulins, following a scientific review conducted by the Medicines and Healthcare Products Regulatory Agency. The ban was imposed in 1998 to mitigate the spread of variant Creutzfeldt Jakob Disease (vCJD), but experts have now concluded that the use of UK-sourced plasma to manufacture immunoglobulins is safe and can recommence, supported by a set of robust safety measures.
Read More
Human Plasma Donations Remain Important During COVID-19 Pandemic +

In a recent communication, the U.S. Food and Drug Administration (FDA) limits the collection and use of COVID-19 convalescent plasma authorized under Emergency Use Authorization for the treatment of hospitalized patients with COVID-19.¹ It is important to note, however, that this development does not mean that the need for plasma donations has diminished. Both normal source plasma donations, from healthy individuals, and convalescent plasma donations, from individuals who have recovered from COVID-19, are still needed to fight COVID-19 and the many non-COVID-19 conditions (e.g., immune deficiencies and blood clotting disorders) for which plasma protein therapies are ordinarily used.
Read More

1
2
3

› ‹

The Source, the international magazine of the plasma protein therapeutics industry, is published quarterly.

Learn more about the need for plasma donors, plasma donation, and how you can save and improve lives. Find a Donation Center.

"How Is Your Day?" is an initiative to raise awareness of the unique nature of plasma protein therapies and the value they provide to patients. It aims to inform and educate decision makers and the general public worldwide.

Get involved and follow "How Is Your Day?" on social media @HIYDglobal

Media and Information

Advocacy

Copyright © 2020 PPTA. All rights reserved. (202) 789-3100

Terms of Use | Privacy Statement | Sitemap